Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase: Unknown; Phase 4

Conditions: Peutz-Jeghers Syndrome

Treatments: Drug: Rapamycin

Study type: Interventional

Funder types: Other

Identifiers

NCT03781050

HS-1607

Details and patient eligibility

About

A prospective non-randomized open label single arm clinical trial to examine the efficacy and safety of sirolimus in patients with Peutz-Jeghers Syndrome.

Full description

PJS (Peutz-Jeghers Syndrome) is mostly caused by mutations in Lkb1 gene, which leads to an increased activity of mTOR pathway, thus making mTOR inhibitor (sirolimus) a promising candidate in treatment and prevention of PJS. The efficacy of sirolimus (rapamycin) on PJS has been demonstrated in mouse model, but no clinical trials have been reported. Our study was designed as a prospective non-randomized open label single arm clinical trial to examine its efficacy and safety.

Enrollment: 10 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients are diagnosed with PJS.

• Patients have gastrointestinal polyps related syndromes, including abdominal pain, abdominal distension, gastrointestinal bleeding, etc, with imageological examination suggesting intestinal obstruction or intussusception; or whose symptoms recur after previous digestive endoscopic treatment and surgery; or who are inappropriate or unwilling to accept the above treatment again and wish to receive pharmacotherapy.

• Conventional treatment didn't work well in patients combined with PJS-related tumors.

• Physical condition (ECGO): 0~3

• Organ function is good and biochemical indices meet the following conditions:

  • AST≤2.5×upper limit of normal value (ULN),
  • ALT≤2.5×upper limit of normal value (ULN),
  • Serum total bilirubin (TSB)≤1.5×upper limit of normal value (ULN),
  • Creatinine≤1.5×upper limit of normal value (ULN).

• No other medications have been received for intestinal polyps within 3 months prior to the clinical trial.

• Patients participate in the trial voluntarily and have signed the informed consent by the participant or his/her legal guardian.

Exclusion criteria

• Patients underwent a surgery within 2 weeks.

• Patients may need emergency surgery in the near future.

• Patients are allergic to any ingredient of rapamycin.

• Patients suffer from a disease requiring immediate blood transfusion.

• Patients suffer from any disease or condition that may impact implementation of the study or interpretation of the results. This type of diseases includes:

  • Known severe blood coagulation disorders
  • Known anemia that is not caused by intestinal polyps
  • Known hemoglobinopathy
  • Other gastrointestinal infectious diseases
  • Serious heart, liver, kidney and other concomitant diseases that may endanger lives

• Patients are in pregnancy and lactation.

• Alcohol or drug (such as aperient) abuse

• Patients took part in another clinical trial that may influence this study.

• The researchers believe that there are other unfavorable reasons for the patient to become a subject.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Rapamycin

Experimental group

Description:

For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months

Treatment:

Drug: Rapamycin